Mersana Therapeutics (STU:0M4) 3-Year Book Growth Rate : -54.80% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics 3-Year Book Growth Rate?

Mersana Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was €0.01.

During the past 12 months, Mersana Therapeutics's average Book Value per Share Growth Rate was -97.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -54.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was -10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Mersana Therapeutics was 63.40% per year. The lowest was -54.80% per year. And the median was -8.85% per year.

Competitive Comparison of Mersana Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Mersana Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's 3-Year Book Growth Rate falls into.

Mersana Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Mersana Therapeutics (STU:0M4) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Mersana Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

MRSN:USA 0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics Headlines

No Headlines